Overall survivals of Thai metastatic triple negative breast cancer patients
Keywords:triple negative breast cancer, overall survival
Triple negative breast cancer (TNBC) is poor prognosis type of breast cancer, especially in patients with metastatic diseases. The treatment options for TNBC are quite limited and overall survival (OS) of metastatic TNBC was shorter compare to other types of breast cancer. There are restricted information regarding to OS of metastatic TNBC in Thais. This study was aimed for finding information about OS and factors related with OS in Thai metastatic TNBC patients. We retrospectively reviewed metastatic TNBC patients’chart in one of university hospital in Bangkok. Relevant information of metastatic TNBC patients who were at least 18 years old who received treatments for their cancer during 1 January to 31 December 2012 to 2016 were collected and analyzed. There were 127 patients included in the study. The average age was 54+13.3 years old, with 78% under 65 years old. The most common metastatic sites were bone and connective tissue, which found 66.1%, followed by lungs, liver at 63.8% and 29.1 %, respectively. Most of patients (38.6%) had 2 metastatic sites and around 64.6% received anthracycline-based regimen as the first line treatment. The second most common chemotherapy for the first line treatment were taxane (19.7%). The median OS in this study was 21.9 months. The survival rate at 1 year, 3 years and 5 years were 45.7%, 10.2% and 3.9 % respectively. The factors which found to associated with OS were metastatic sites. Patients with liver, lungs, or bone metastasis had significantly shorter OS. Moreover, older patients (>65 years old) tended to have longer OS (16.7 vs 13.2 months, P = 0.081). Patients treated with taxane as the first line chemotherapy had longer OS with not statistically significance. We conclude that the factors seem to impact overall survival of Thai metastatic TNBC were metastatic sites and patients’age.
Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021 May; 71(3):209-249. doi: 10.3322/caac.21660. Epub 2021 Feb 4. PMID: 33538338.
สถาบันมะเร็งแห่งชาติ. Cancer registry 2020. https://www.nci.go.th/th/cancer_record/cancer_
Li X, Yang J, Peng L, Sahin AA, Huo L, Ward KC, et al. Triple-negative breast cancer has worse overall survival and cause-specific survival than non-triple-negative breast cancer. Breast Cancer Res Treat. 2017 Jan; 161(2):279-87. doi: 10.1007/s10549-016-4059-6. Epub 2016 Nov 25. PMID: 27888421.
Agarwal G, Nanda G, Lal P, Mishra A, Agarwal A, Agrawal V, et al. Outcomes of Triple-Negative Breast Cancers (TNBC) Compared with Non-TNBC: Does the Survival Vary for All Stages? World J Surg. 2016 Jun; 40(6): 1362-72. doi: 10.1007/s00268-016-3422-4. PMID: 26842691.
Srimuninnimit V, Pornpraserthsuk P, Chaiwerawattana A, Kongdan Y, Namkanisorn T, Somwangprasert A, et al. Real-life clinical pattern, management, and survival in Thai patients with early-stage or metastatic triple-negative breast cancer. PloS one. 2018 Dec 19;13(12):e0209040.
Laohavinij S, Paul V, Maneenil K. Survival and Prognostic Factors of Metastatic Breast Cancer. Journal of the Medical Association of Thailand= Chotmaihet Thangphaet. 2017 Feb 1;100:S16-26.
Morris GJ, Naidu S, Topham AK, Guiles F, Xu Y, McCue P, et al. Differences in breast carcinoma characteristics in newly diagnosed African-American and Caucasian patients: a single-institution compilation compared with the National Cancer Institute's Surveillance, Epidemiology, and End Results database. Cancer. 2007 Aug 15; 110(4):876-84.doi: 10.1002/cncr.22836. PMID: 17620276.
Agarwal G, Nanda G, Lal P, Mishra A, Agarwal A, Agarwal V, et al. Outcomes of Triple-Negative Breast Cancers (TNBC) Compared with Non-TNBC: Does the Survival Vary for All Stages?. World J Surg 40, 1362–1372 (2016). https://doi.org/10.1007/s00268-016-3422-4
Liedtke C, Hess K. R, Karn T, Rody A, Kiesel L, Hortobagyi G N, et al. The prognostic impact of age in patients with triple-negative breast cancer. Breast Cancer Res Treat 138, 591–599 (2013). https://doi.org/10.1007/s10549-013-2461-x
Sun Li, Zhu Yulan, Qian Qi, Tang Liming. Body mass index and prognosis of breast cancer: An analysis by menstruation status when breast cancer diagnosis. Medicine (Baltimore) 2018 Jun; 97(26):e11220.doi: 10.1097/MD.0000000000011220
Alarfi H, Salamoon M, Kadri M, Alammar M, Haykal A. M, Alseoudi A, et al. The impact of baseline body mass index on clinical outcomes in metastatic breast cancer: a prospective study. BMC Res Notes 10, 550 (2017). https://doi.org/10.1186/s13104-017-2876-2
Wang R, Zhu Y, Liu X, Liao X, He J, Niu L. The Clinicopathological features and survival outcomes of patients with different metastatic sites in stage IV breast cancer. BMC cancer. 2019 Dec; 19(1):1-2.
Copyright (c) 2023 Thailand's National Cancer Institute Foundation
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
บทความทีตีพิมพ์ในวารสารโรคมะเร็งนี้ถือว่าเป็นลิขสิทธิ์ของมูลนิธิสถาบันมะเร็งแห่งชาติ และผลงานวิชาการหรือวิจัยของคณะผู้เขียน ไม่ใช่ความคิดเห็นของบรรณาธิการหรือผู้จัดทํา